| scholarly article | Q13442814 |
| P50 | author | Christopher R Chapple | Q37831462 |
| Philip Toozs-Hobson | Q57756333 | ||
| P2093 | author name string | D M Wright | |
| J Bolodeoku | |||
| L Selvaggi | |||
| W Warnack | |||
| R Martinez-Garcia | |||
| STAR study group | |||
| T Drogendijk | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 464-470 | |
| P577 | publication date | 2005-09-01 | |
| P1433 | published in | European Urology | Q15763991 |
| P1476 | title | A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial | |
| P478 | volume | 48 |
| Q36879656 | A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting |
| Q38345883 | A review of cost-effectiveness comparisons for overactive bladder treatments: which is the most cost-effective for improving quality of life? |
| Q36822864 | A review of solifenacin in the treatment of urinary incontinence. |
| Q34112974 | AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder |
| Q39020998 | Adverse events and treatment discontinuations of antimuscarinics for the treatment of overactive bladder in older adults: A systematic review and meta-analysis |
| Q35042575 | An overview of the clinical use of antimuscarinics in the treatment of overactive bladder |
| Q34568286 | Anticholinergics for overactive bladder: does subtype selectivity play a role? |
| Q51817526 | Antimuscarinic drugs for the treatment of female urinary incontinence. |
| Q37484824 | Behavioral intervention versus pharmacotherapy or their combinations in the management of overactive bladder dysfunction |
| Q33748111 | Behavioral treatment of insomnia: also effective for nocturia |
| Q50054306 | Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base |
| Q37946313 | Botulinum toxin treatment for overactive bladder and detrusor overactivity in adults |
| Q42944274 | Canadian cost-effectiveness analysis of solifenacin compared to oxybutynin immediate-release in patients with overactive bladder |
| Q38116972 | Cardiovascular effects of antimuscarinic agents in overactive bladder. |
| Q46592044 | Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study |
| Q37192944 | Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin |
| Q40963346 | Clinical Guideline for Female Lower Urinary Tract Symptoms |
| Q37697655 | Clinical factors associated with dose escalation of solifenacin for the treatment of overactive bladder in real life practice. |
| Q43087475 | Clinical guidelines for nocturia |
| Q46116817 | Clinical guidelines for overactive bladder |
| Q37535961 | Clinical pharmacokinetics and pharmacodynamics of solifenacin |
| Q35535376 | Combination therapies for the management of nocturia and its comorbidities |
| Q35419834 | Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study) |
| Q79521323 | Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride |
| Q51474348 | Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. |
| Q81706385 | Concomitant medications and possible side effects of antimuscarinic agents |
| Q37582301 | Considerations for the management of urgency symptoms in patients with overactive bladder syndrome |
| Q34408830 | Content validity and test-retest reliability of Patient Perception of Intensity of Urgency Scale (PPIUS) for overactive bladder |
| Q36428481 | Cost implications of antimuscarinic drugs in the treatment of overactive bladder syndrome |
| Q34077022 | Cost-effectiveness analysis of newer anticholinergic drugs for urinary incontinence vs oxybutynin and no treatment using data on persistence from the Swedish prescribed drug registry. |
| Q54962623 | Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK. |
| Q36568728 | Current and emerging investigational medical therapies for the treatment of overactive bladder |
| Q38095986 | Current pharmacotherapy of nocturia |
| Q35113508 | Current trends in the evaluation and management of female urinary incontinence |
| Q37700257 | Detrusor overactivity: an overview |
| Q31095754 | Disease burden of overactive bladder: quality-of-life data assessed using ICI-recommended instruments |
| Q39581997 | Does conservative management really benefit patients with OAB? |
| Q33692394 | Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence |
| Q37438829 | Drug treatment of bothersome lower urinary tract symptoms after ureteric JJ-stent insertion: A contemporary, comparative, prospective, randomised placebo-controlled study, single-centre experience |
| Q37884068 | Drugs with anticholinergic properties: a current perspective on use and safety. |
| Q37283751 | Effect of baseline symptom severity on continence improvement mediated by oxybutynin chloride topical gel. |
| Q48231452 | Effect of imidafenacin on nocturia and sleep disorder in patients with overactive bladder. |
| Q35966051 | Effects of a Gentle, Self-Administered Stimulation of Perineal Skin for Nocturia in Elderly Women: A Randomized, Placebo-Controlled, Double-Blind Crossover Trial |
| Q85711630 | Effects of solifenacin in patients with neurogenic detrusor overactivity as a result of spinal cord lesion |
| Q37672836 | Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladder |
| Q37187453 | Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study |
| Q43264398 | Efficacy of simplified bladder training in patients with overactive bladder receiving a solifenacin flexible-dose regimen: results from a randomized study |
| Q34618648 | Emerging drugs for treatment of urinary incontinence |
| Q37809726 | Etiology and Treatment of Overactive Bladder in Women |
| Q37634191 | Fesoterodine for the treatment of overactive bladder |
| Q33588346 | Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain |
| Q36946067 | How to choose the initial drug treatment for overactive bladder |
| Q81339776 | Human urine with solifenacin intake but not tolterodine or darifenacin intake blocks detrusor overactivity |
| Q44260220 | Is solifenacin succinate safe and effective for the treatment of overactive bladder? |
| Q37457080 | Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome |
| Q46351979 | Long-term safety and efficacy of two different antimuscarinics, imidafenacin and solifenacin, for treatment of overactive bladder: a prospective randomized controlled study |
| Q35801020 | M2 mediated contractions of human bladder from organ donors is associated with an increase in urothelial muscarinic receptors |
| Q36875672 | Management of overactive bladder syndrome |
| Q84757653 | Management of urinary incontinence |
| Q36815273 | Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached? |
| Q34124065 | Medical management of overactive bladder |
| Q34699525 | Muscarinic receptor antagonists for overactive bladder |
| Q34564708 | Muscarinic receptors in the bladder: from basic research to therapeutics |
| Q58269335 | Nocturia in patients with benign prostatic hyperplasia: evaluating the significance of ageing, co-morbid illnesses, lifestyle and medical therapy in treatment outcome in real life practice |
| Q38049167 | Nocturia: current concepts and future perspectives |
| Q36965934 | Nocturia: etiology, diagnosis, and treatment |
| Q79197254 | Of porcupines and poodles--a joint challenge to industry and the profession |
| Q37868803 | Outcomes of pharmacological management of nocturia with non-antidiuretic agents: does statistically significant equal clinically significant? |
| Q53945500 | Overactive Bladder Syndrome: Evaluation and Management. |
| Q36779724 | Overactive bladder syndrome in older people |
| Q36596773 | Overactive bladder: The importance of new guidance. |
| Q37699370 | Overactive bladder: diagnosis and treatment |
| Q39246328 | Patient-reported goal achievement after antimuscarinic treatment in patients with overactive bladder symptoms |
| Q83811785 | Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin |
| Q37947438 | Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure? |
| Q39279571 | Patient‐optimized doses of fesoterodine improve bladder symptoms in an open‐label, flexible‐dose study |
| Q50920922 | Pelvic floor dysfunction in female Sjögren's syndrome: an 8-year audit. |
| Q37864717 | Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature |
| Q26765014 | Persistence and compliance with medication management in the treatment of overactive bladder |
| Q45354034 | Persistence of antimuscarinic drug use. |
| Q37017434 | Pharmacologic management of overactive bladder |
| Q36563410 | Pharmacotherapy for overactive bladder: an evidence-based approach to selecting an antimuscarinic agent |
| Q82574887 | Pharmacotherapy of urinary incontinence |
| Q55239684 | Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database. |
| Q40216118 | Randomized, Single-Blind, Parallel Study of the Effectiveness and Safety of Solifenacin versus Propiverine in the Treatment of Overactive Bladder |
| Q36239162 | Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospium chloride in the relief of double-J stent-related symptoms. |
| Q33560320 | Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin. |
| Q42615594 | Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS. |
| Q37914849 | Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder |
| Q51839285 | Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE). |
| Q37283547 | Social, economic, and health utility considerations in the treatment of overactive bladder |
| Q42679416 | Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms |
| Q37226401 | Solifenacin at 3 years: a review of efficacy and safety |
| Q48475293 | Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes |
| Q37981898 | Solifenacin for overactive bladder: a systematic review and meta-analysis |
| Q59187152 | Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy |
| Q34563524 | Solifenacin in overactive bladder syndrome |
| Q82442161 | Solifenacin in overactive bladder syndrome |
| Q46259970 | Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial |
| Q87790295 | Solifenacin is able to improve the irritative symptoms after transurethral resection of bladder tumors |
| Q36655193 | Solifenacin provides effective antimuscarinic therapy for the complete management of overactive bladder |
| Q30445725 | Solifenacin significantly improves all symptoms of overactive bladder syndrome |
| Q36608356 | Solifenacin. |
| Q38177369 | Solifenacin: pharmacology and clinical efficacy |
| Q46598599 | Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head‐to‐head, placebo‐controlled trial |
| Q48609644 | Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial |
| Q35875556 | The Relations between Enuresis in Childhood and Nocturnal Polyuria Syndrome in Adult Life |
| Q37890031 | The evaluation and treatment of nocturia: a consensus statement |
| Q37836943 | The medical treatment of overactive bladder, including current and future treatments. |
| Q37199946 | The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly |
| Q34502903 | Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review |
| Q34610640 | Tolterodine extended-release for overactive bladder |
| Q37142090 | Tolterodine for the treatment of overactive bladder |
| Q36608347 | Tolterodine for treatment of overactive bladder. |
| Q38543432 | Tolterodine in the Treatment of Male LUTS. |
| Q27001248 | Total urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptoms |
| Q46257093 | Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial |
| Q34508835 | Treatments for overactive bladder: focus on pharmacotherapy |
| Q28308162 | Trospium chloride treatment of overactive bladder |
| Q37283585 | Update on tolterodine extended-release for treatment of overactive bladder |
| Q38193878 | Urinary incontinence in the young woman: treatment plans and options available |
| Q36627923 | Urinary incontinence: economic burden and new choices in pharmaceutical treatment |
| Q37884579 | Urinary incontinence: pharmacotherapy options |
| Q24203880 | Which anticholinergic drug for overactive bladder symptoms in adults |
| Q79830097 | [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder] |
| Q54695790 | [Treatment for overactive bladder]. |
Search more.